Glen Clova Scientific
Developing a new generation of Active Biologic Drugs
Our Vision
- To move beyond current Biologic drugs and create Active Biologic drugs allowing patients to form natural antibodies against harmful targets.
- To make high quality treatment for chronic disease available for a demographic not able to access conventional Biologic drugs and contribute toward affordable healthcare globally.
Business Strategy
Growth through:
- Development of both platform and product IP
- License specific drug candidates emanating from the proprietary platform (GCS001 – 003)
- License technology to partners in fields outside of human health applications
Transforming the clinical potential of biologic drugs
The Problem
Biological drugs, e.g. antibodies, are hugely successful but market penetration for many indications is incomplete due to inherent limitations including:
- Frequent dosing (every 2 – 4 weeks for most MAbs)
- Requirement for frequent patient sampling and analysis for safety monitoring
- Complex manufacture combined with a requirement for a high amount of drug per patient
- High Cost of Goods Sold (CGS) limits opening of new markets and implementation in existing markets
The Solution
A new class of Active Biologics featuring:
- Reduced frequency of dosing (1-2 doses for induction, 1-2 boosts per year) - significant improvement in pharmaco-economics
- Reduced drug per dose (microgram instead of milligram) - significant improvement in cost per patient
- Reduced safety monitoring needed - reducing overall cost of treatment and opening markets with limited infrastructure
What’s unique about GCS technology?
- Single cell bank for VLP scaffold and displayed protein - single release drug
- No requirement for genetic fusion of displayed protein
- No requirement for covalent / chemical linkage of displayed protein
- Generic purification scheme applicable to any displayed protein
- Built-in chaperone for difficult-to-express proteins
